Topics

Latest "Progress Stem Cell Science Regenerative Medicine Angeles June" News Stories

02:42 EST 15th November 2019 | BioPortfolio

Here are the most relevant search results for "Progress Stem Cell Science Regenerative Medicine Angeles June" found in our extensive news archives from over 250 global news sources.

More Information about Progress Stem Cell Science Regenerative Medicine Angeles June on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Progress Stem Cell Science Regenerative Medicine Angeles June for you to read. Along with our medical data and news we also list Progress Stem Cell Science Regenerative Medicine Angeles June Clinical Trials, which are updated daily. BioPortfolio also has a large database of Progress Stem Cell Science Regenerative Medicine Angeles June Companies for you to search.

Showing "Progress Stem Cell Science Regenerative Medicine Angeles June" News Articles 1–25 of 31,000+

Friday 15th November 2019

2019 Glucose Intolerance Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Report Updated: 24042019] Prices from USD $1799

The global clinical trial report 2019 Glucose Intolerance Clinical Trials Study provides complete list of trials completed, ongoing and planned for Glucose Intolerance. It presents indepth analysis of Glucose Intolerance clinical trials across markets and companies. The research work is for providing complete understanding into trends in Glucose Intolerance. The report covers a key snapshot of tr...


Thursday 14th November 2019

After winning regulatory approval late last month for its new multiple sclerosis drug, Biogen boasted to a patient group that its pill would cost $88,000, which meant it would have the “lowest annual” wholesale price of any such medicine. https://buff

After winning regulatory approval late last month for its new multiple sclerosis drug, Biogen boasted to a patient group that its pill would cost $88,000, which meant it would have the “lowest annual” wholesale price of any such medicine. https://buff.ly/32PhLqj 

2019 Fatty Liver Disease Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Report Updated: 24042019] Prices from USD $1799

The global clinical trial report 2019 Fatty Liver Disease Clinical Trials Study provides complete list of trials completed, ongoing and planned for Fatty Liver Disease. It presents indepth analysis of Fatty Liver Disease clinical trials across markets and companies. The research work is for providing complete understanding into trends in Fatty Liver Disease. The report covers a key snapshot of tr...


2019 Cellulite Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Report Updated: 24042019] Prices from USD $1799

The global clinical trial report 2019 Cellulite Clinical Trials Study provides complete list of trials completed, ongoing and planned for Cellulite. It presents indepth analysis of Cellulite clinical trials across markets and companies. The research work is for providing complete understanding into trends in Cellulite. The report covers a key snapshot of trial trends, enrollment trends, success t...

FETROJA® (cefiderocol) Approved by the FDA for Treatment of Complicated Urinary Tract Infections (cUTI) in Adult Patients with Limited or No Alternative Treatment Options

FETROJA is the first approved antibiotic that functions as a siderophore FETROJA binds to free iron to gain additional cell entry FETROJA demonstrated higher response rates versus imipenem/cilastatin in a cUTI study Shionogi & Co., Ltd. (hereafter “Shionogi”) today announced the U.S. Food and Drug Administration (FDA) has approved FETROJA® (cefiderocol) for patients 18 years of age...

2019 Hand, Foot and Mouth Disease Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Report Updated: 24042019] Prices from USD $1799

The global clinical trial report 2019 Hand, Foot and Mouth Disease Clinical Trials Study provides complete list of trials completed, ongoing and planned for Hand, Foot and Mouth Disease. It presents indepth analysis of Hand, Foot and Mouth Disease clinical trials across markets and companies. The research work is for providing complete understanding into trends in Hand, Foot and Mouth Disease. Th...

FDA Approves Zanubrutinib for Relapsed/Refractory MCL

The FDA has granted an accelerated approval to zanubrutinib capsules for the treatment of adult patients with mantle cell lymphoma who have received ≥1 prior therapy.

Changing of the guard at Science & Technology Australia

Science & Technology Australia (STA), Australia’s peak body in science and technology, has announced the appointment of three newly elected members to its board: Associate Professor Christopher Fulton (Aquatic Sciences), Dr Kathy Nicholson (General Sciences) and Dr Karen Gregory (Medical and Cognitive Sciences). They replace outgoing board members Professor Rebecca Ritchie, Dr Katherine Daf...

B&D Dental Corp. Announces Issuance of Comprehensive US Patent for Dental Zirconia

B&D Dental Corp. (“B&D”) announced today that the United States Patent and Trademark Office has issued US Patent 10,463,457, covering a wide spectrum of dental zirconia-based products utilized by dental laboratories throughout the industry. This new patent issuance increases B&D’s total patent portfolio to 12 issued patents, 8 of which are specifically related to dental zirconia...

2019 Postmenopausal Vaginal Atrophy Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Report Updated: 24042019] Prices from USD $1799

The global clinical trial report 2019 Postmenopausal Vaginal Atrophy Clinical Trials Study provides complete list of trials completed, ongoing and planned for Postmenopausal Vaginal Atrophy. It presents indepth analysis of Postmenopausal Vaginal Atrophy clinical trials across markets and companies. The research work is for providing complete understanding into trends in Postmenopausal Vaginal Atr...

Otezla May Give Oral Ulcer Relief in Patients With Recurrent Aphthous Stomatitis

A drug approved by the U.S. Food and Drug Administration in July to treat oral ulcers in patients with Behcet's syndrome may be a candidate for helping people with treatment-refractory recurrent aphthous stomatitis, according to correspondence from Swiss doctors published Wednesday online in The New England Journal of Medicine. Reuters Health Information

Study examines how drug promotion rules influence physician prescribing practices

Findings from a new study led by researchers at Dartmouth's Geisel School of Medicine and Harvard Medical School and published in the journal Circulation: Cardiovascular Quality and Outcomes, show that the way in which pharmaceutical companies are permitted to share information about their drugs can influence physician prescribing practices.

2019 Metastatic Uveal Melanoma Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Report Updated: 24042019] Prices from USD $1799

The global clinical trial report 2019 Metastatic Uveal Melanoma Clinical Trials Study provides complete list of trials completed, ongoing and planned for Metastatic Uveal Melanoma. It presents indepth analysis of Metastatic Uveal Melanoma clinical trials across markets and companies. The research work is for providing complete understanding into trends in Metastatic Uveal Melanoma. The report cov...

2019 Snoring Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Report Updated: 24042019] Prices from USD $1799

The global clinical trial report 2019 Snoring Clinical Trials Study provides complete list of trials completed, ongoing and planned for Snoring. It presents indepth analysis of Snoring clinical trials across markets and companies. The research work is for providing complete understanding into trends in Snoring. The report covers a key snapshot of trial trends, enrollment trends, success trends, l...

Cleveland BioLabs, Inc: Cleveland BioLabs Reports Third Quarter 2019 Financial Results and Development Progress

BUFFALO, NY / ACCESSWIRE / November 14, 2019 / Cleveland BioLabs, Inc. (NASDAQ:CBLI) today reported financial results and development progress for the third quarter ended September 30, 2019. Clevel...

US approves BeiGene's BTK inhibitor Brukinsa for mantle cell lymphoma https://www.firstwordpharma.com/node/1681236 

US approves BeiGene's BTK inhibitor Brukinsa for mantle cell lymphoma https://www.firstwordpharma.com/node/1681236 

Biogennix Teams with Second Harvest Food Bank to Give Back to the Community

Biogennix, an osteobiologics company that develops, manufactures, and distributes proprietary bone graft products used for bone fusion procedures, spent a recent afternoon celebrating the spirit of Thanksgiving early. The company and its employees chose to donate a Wednesday afternoon supporting Second Harvest Food Bank of Orange County. Second Harvest is the largest nonprofit hunger relief org...

RJH Biosciences Inc. to Receive Funding Under Grand Challenges Explorations Initiative

RJH Biosciences to develop a revolutionary immunotherapy approach RJH Biosciences Inc. has announced a grant from the Bill & Melinda Gates Foundation to develop a new device to enable ‘Immunotherapy On-the-Go’. RJH Biosciences Inc., a privately held biotech company in Edmonton, Alberta, will pursue a Phase I Project under the Grand Challenges Explorations initiative to develop a new mode...

Magistrate Judge Issues Report and Recommendation to Award KORU Medical Systems $1.0 Million in Attorneys’ Fees and Costs

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”) today announced that on November 12, 2019 a United States District Court Magistrate Judge for the Southern District of New York issued a Report and Recommendation that KORU Medical’s motion to declare the patent infringement case exceptional and recoup attorneys’ fees and expenses from EM...

Tricida Announces Third Quarter 2019 Financial Results

FDA Accepts New Drug Application for Veverimer Webcast Today at 4:30 pm Eastern Time Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today financial results fo...

Bioasis Announces Issuance of Japanese Patent Relating to xB3™ Platform Technology for The Delivery of Therapeutic Agents Across The Blood-Brain Barrier

Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain canc...

Second Sight Reports Third Quarter 2019 Financial Results

-- Reached agreement with FDA regarding the primary efficacy endpoint for the Orion pivotal trial -- Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today reported financial results for the th...

Tricida Announces FDA Acceptance of New Drug Application for Veverimer

Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for ...

AgeX Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

Advanced GMP-compliant manufacturing capability Published two peer-reviewed scientific papers Included in MIT Technology Review Special Issue on Longevity Presented at industry and investor conferences AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported financial and operating results for th...

WPI Engineers Creating Miniaturized, Wireless Oxygen Sensor for Sick Infants

Mobile, wearable device the size of a Band-Aid could allow babies to leave the hospital and be monitored from home. WORCESTER, Mass. (PRWEB) November 14, 2019 Researchers at Worcester Polytechnic Institute (WPI) are developing a sensor the size of a Band-Aid that will measure a baby’s blood oxygen levels, a vital indication of the lungs’ effectiveness and whether the baby’s tissue is receiv...


Quick Search

News Quicklinks